Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

13:39
10/21/18
10/21
13:39
10/21/18
13:39

Entrectinib shrank tumors in people with NTRK fusion-positive solid tumors

Genentech, a member of the Roche, announced results from an integrated analysis of the pivotal Phase II STARTRK-2, Phase I STARTRK-1 and Phase I ALKA-372-001 trials that showed the investigational personalized medicine entrectinib shrank tumors in more than half of people with neurotrophic tropomyosin receptor kinase fusion-positive solid tumors. Objective responses to entrectinib were seen across 10 different solid tumor types, including in people with and without central nervous system metastases at baseline. Importantly, entrectinib shrank tumors that had spread to the brain in over half of people, with more than a quarter of these people having a complete response. The safety profile of entrectinib was consistent with that seen in previous analyses. Entrectinib has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for the treatment of NTRK fusion-positive, locally advanced or metastatic solid tumors in adult and pediatric patients who have either progressed following prior therapies or have no acceptable standard therapies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases and to help ensure people have access to them through FDA approval as soon as possible. Genentech plans to submit results from these integrated analyses to global health authorities for the treatment of NTRK fusion-positive solid tumors and ROS1-positive NSCLC.

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

TELL

Tellurian

$8.33

-0.1 (-1.19%)

20:44
09/17/19
09/17
20:44
09/17/19
20:44
Initiation
Tellurian initiated  »

Tellurian initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

20:41
09/17/19
09/17
20:41
09/17/19
20:41
Initiation
NextDecade initiated  »

NextDecade initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LINX

Linx S.A.

$7.74

0.22 (2.93%)

20:32
09/17/19
09/17
20:32
09/17/19
20:32
Recommendations
Linx S.A. analyst commentary  »

Linx S.A. offers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Conference/Events
Morgan Stanley steel analyst to hold an analyst/industry conference call »

China Materials Analyst…

GIS

General Mills

$55.03

0.48 (0.88%)

20:25
09/17/19
09/17
20:25
09/17/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 24

    Sep

  • 01

    Oct

ROAD

Construction Partners

$14.39

-0.42 (-2.84%)

20:10
09/17/19
09/17
20:10
09/17/19
20:10
Syndicate
Construction Partners 5M share Secondary priced at $14.25 »

Construction Partners 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

  • 18

    Sep

NVST

Envista

$0.00

(0.00%)

19:58
09/17/19
09/17
19:58
09/17/19
19:58
Syndicate
Envista 26.77M share IPO priced at $22.00 »

The deal priced inside…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 18

    Sep

INVH

Invitation Homes

$28.49

0.31 (1.10%)

19:51
09/17/19
09/17
19:51
09/17/19
19:51
Syndicate
Invitation Homes 44M share Spot Secondary priced at $28.25 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

, NCMI

National CineMedia

$8.35

0.25 (3.09%)

19:49
09/17/19
09/17
19:49
09/17/19
19:49
Hot Stocks
AMC Entertainment corrects 'inaccurate' statement by National CineMedia »

AMC Entertainment (AMC)…

AMC

AMC Entertainment

$11.46

-0.46 (-3.86%)

NCMI

National CineMedia

$8.35

0.25 (3.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

BA

Boeing

$384.61

5.74 (1.52%)

19:01
09/17/19
09/17
19:01
09/17/19
19:01
Hot Stocks
House panel invites Boeing CEO to testify on 737 MAX »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

O

Realty Income

$75.76

1.81 (2.45%)

18:56
09/17/19
09/17
18:56
09/17/19
18:56
Hot Stocks
Realty Income raises monthly cash dividend to 22.7c per share from 22.65c »

Realty Income Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

, CDW

CDW

$113.91

0.94 (0.83%)

18:54
09/17/19
09/17
18:54
09/17/19
18:54
Hot Stocks
Fly Intel: After Hours Movers »

HIGHER: NewLink (NLNK) up…

NLNK

NewLink Genetics

$1.90

-0.03 (-1.55%)

CDW

CDW

$113.91

0.94 (0.83%)

TELL

Tellurian

$8.33

-0.1 (-1.19%)

NEXT

NextDecade

$6.30

-0.1 (-1.56%)

FDX

FedEx

$173.53

-0.14 (-0.08%)

XPO

XPO Logistics

$73.83

-0.76 (-1.02%)

CHWY

Chewy

$30.20

-0.2 (-0.66%)

ADBE

Adobe

$284.59

1.54 (0.54%)

IOTS

Adesto Technologies

$10.63

-0.66 (-5.85%)

PTCT

PTC Therapeutics

$43.26

0.27 (0.63%)

TBIO

Translate Bio

$11.01

0.405 (3.82%)

ACAD

Acadia

$42.60

-1.45 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 17

    Sep

  • 23

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 23

    Oct

  • 27

    Oct

  • 13

    Nov

  • 18

    Sep

  • 18

    Sep

  • 18

    Sep

YUMA

Yuma Energy

$5.08

-0.05 (-0.97%)

18:51
09/17/19
09/17
18:51
09/17/19
18:51
Hot Stocks
Yuma Energy enters forbearance agreement with lender YE Investment »

Yuma Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$284.59

1.54 (0.54%)

18:45
09/17/19
09/17
18:45
09/17/19
18:45
Hot Stocks
Adobe CEO: We experienced growth across all of our segments »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Oct

  • 27

    Oct

ARAY

Accuray

$3.09

-0.03 (-0.96%)

18:37
09/17/19
09/17
18:37
09/17/19
18:37
Hot Stocks
Data in Lancet Oncology discloses lower toxicity for Accuray Cyberknife patients »

Accuray announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FBK

FB Financial

$38.33

-0.36 (-0.93%)

18:29
09/17/19
09/17
18:29
09/17/19
18:29
Hot Stocks
FB Financial acquires FNB Financial »

FB Financial, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

  • 13

    Nov

GM

General Motors

$38.28

1.07 (2.88%)

18:28
09/17/19
09/17
18:28
09/17/19
18:28
Periodicals
GM stops paying health insurance costs for union workers on strike, Reuters says »

General Motors has moved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOT

Total

$52.85

0.08 (0.15%)

18:25
09/17/19
09/17
18:25
09/17/19
18:25
Periodicals
Total CEO says Saudi oil facility strikes will have consequences, Reuters says »

Total CEO Patrick…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

SMMF

Summit Financial Group

$25.96

-0.29 (-1.10%)

18:02
09/17/19
09/17
18:02
09/17/19
18:02
Hot Stocks
Summit Financial and Cornerstone Financial sign merger agreement »

Summit Financial Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STLD

Steel Dynamics

$30.93

-0.89 (-2.80%)

18:01
09/17/19
09/17
18:01
09/17/19
18:01
Earnings
Steel Dynamics sees Q3 EPS 66c-70c, consensus 71c »

Steel Dynamics provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDX

FedEx

$173.53

-0.14 (-0.08%)

18:00
09/17/19
09/17
18:00
09/17/19
18:00
Hot Stocks
Breaking Hot Stocks news story on FedEx »

FedEx says FY21 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

FDX

FedEx

$173.53

-0.14 (-0.08%)

17:59
09/17/19
09/17
17:59
09/17/19
17:59
Hot Stocks
FedEx says new FY20 EPS forecast assumes no further weakening in economic growth »

Says FY20 ground…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 13

    Nov

BTI

British American Tobacco

$36.84

0.825 (2.29%)

, PM

Philip Morris

$71.98

-0.54 (-0.74%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
General News
NY State implements first-in-nation ban on flavored e-cigarettes »

Governor Andrew M. Cuomo…

BTI

British American Tobacco

$36.84

0.825 (2.29%)

PM

Philip Morris

$71.98

-0.54 (-0.74%)

MO

Altria Group

$41.31

-0.1 (-0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

MRK

Merck

$82.53

0.52 (0.63%)

17:57
09/17/19
09/17
17:57
09/17/19
17:57
Hot Stocks
Merck says FDA approves Keytruda-Lenvima combo treatment »

Merck and Eisai announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Sep

  • 20

    Sep

  • 24

    Sep

  • 27

    Sep

  • 02

    Oct

  • 03

    Oct

  • 29

    Oct

ENB

Enbridge

$35.27

0.1 (0.28%)

17:56
09/17/19
09/17
17:56
09/17/19
17:56
Hot Stocks
Enbridge says Minnesota Supreme Court rejects L3RP FEIS appeals »

Enbridge said it supports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.